GenVec, Inc. :GNVC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016

GenVec, Inc. reports financial results for the quarter ended September 30, 2016.

We analyze the earnings along side the following peers of GenVec, Inc. – Pfizer Inc., Novartis AG Sponsored ADR, Merck & Co., Inc., Sangamo BioSciences, Inc. and Johnson & Johnson (PFE-US, NVS-US, MRK-US, SGMO-US and JNJ-US) that have also reported for this period.


  • Summary numbers: Revenues of USD 0.17 million, Net Earnings of USD -1.21 million.
  • Earnings growth due to contribution of one-time items.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2015-09-30 2015-12-31 2016-03-31 2016-06-30 2016-09-30
Relevant Numbers (Quarterly)
Revenues (mil) 0.19 0.16 0.29 0.03 0.17
Revenue Growth (%YOY) -23.41 -95.47 -28.4 -79.53 -10.36
Earnings (mil) -1.51 -1.64 -1.86 -1.2 -1.21
Earnings Growth (%YOY) 5.7 -195.69 -21.65 36.06 19.8
Net Margin (%) -779.79 -1026.25 -641.38 -4596.15 -697.69
EPS -0.09 -0.1 -0.11 -0.06 -0.05
Return on Equity (%) -62.16 -78.43 -108.56 -72.9 -73.53
Return on Assets (%) -52.26 -64.66 -86.97 -52.61 -48.78

Access our Ratings and Scores for GenVec, Inc.

Market Share Versus Profits

Revenues History
Earnings History

GNVC-US‘s change in revenue this period compared to the same period last year of -10.36% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that GNVC-US is holding onto its market share. Also, for comparison purposes, revenues changed by 565.38% and earnings by -1.00% compared to the immediate last period.

Revenues Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Leader, Earnings Focus, Laggard, Revenues Focus


The company’s operating (EBIT) margins contracted from -782.90% to -884.39%. In spite of this, the company’s earnings rose. This was influenced primarily by one-time items, which improved pretax margins from -779.79% to -697.69%.

EBIT Margin Versus PreTax Margin

Quadrant label definitions. Hover to know more

Operation driven Earnings, One-time Favorables, Low Earnings Base, One-time Unfavorables
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for GenVec, Inc.

Company Profile

GenVec, Inc. is a clinical-stage biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. It is working with other companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. It’s development programs address therapeutic areas such as hearing loss, balance disorders and cancer; as well as vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, dengue fever and malaria. The company was founded in December 1992 and is headquartered in Gaithersburg, MD.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of GNVC-US.